Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
Authors Lapuz C, Enjeti AK, O'Brien PC, Capp AL, Holliday EG, Gupta SA
Received 20 December 2017
Accepted for publication 1 February 2018
Published 18 April 2018 Volume 2018:8 Pages 13—20
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor David Dingli
Carminia Lapuz,1–3 Anoop K Enjeti,2,4 Peter C O’Brien,1,2 Anne L Capp,1,2 Elizabeth G Holliday,2,5 Sanjiv A Gupta1,2
1Department of Radiation Oncology, Calvary Mater Newcastle, Newcastle, NSW, Australia; 2Faculty of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia; 3Department of Radiation Oncology, Olivia Newton-John Cancer Centre, Austin Health, VIC, Australia; 4Department of Haematology, Calvary Mater Newcastle, Newcastle, NSW, Australia; 5Faculty of Public Health, Hunter Medical Research Institute, Newcastle, NSW, Australia
Background: This study evaluated relapse patterns and survival in advanced Hodgkin lymphoma (HL) patients treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) with positron emission tomography (PET) used for staging and response assessment.
Patients and methods: Patients aged 18 years or above with newly diagnosed histologically proven Stage III or IV HL treated with ABVD at Calvary Mater Newcastle from January 2005 to December 2012 were included in this study. All patients underwent pre-chemotherapy staging with 18F-fluorodeoxyglucose PET or PET/computed tomography and post-chemotherapy PET or PET/computed tomography for the assessment of response.
Results: Forty-three patients were included in the study. The 5-year disease-free survival, progression-free survival and overall survival were 88%, 74% and 86%, respectively. PET complete response was seen in 35 patients (81%), and the 5-year overall survival for this group was 94%. Relapse following a PET complete response was low (three patients) and occurred predominantly at the initial sites of disease. Four of five patients with bulky disease received consolidative radiotherapy and no in-field relapses were observed.
Conclusion: Advanced stage HL with a PET complete response following ABVD is associated with an excellent prognosis.
Keywords: Hodgkin lymphoma, advanced, PET scan
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]